The Mycetoma Open Source (MycetOS) project was launched by the University of Sydney, Erasmus MC, and DNDi, using an open source approach to discover potential treatments for mycetoma. Daiichi Sankyo Europe GmbH ... the end of the calendar year will be disclosed as part of the next annual reporting period because the payment may not occur until … 459 members, from over 150 institutions and 24 countries, Founded in 2014 in Rio de Janeiro, Brazil, Founded in 2005 in Kinshasa, Democratic Republic of Congo, 2018 Daiichi Sankyo Co. Ltd. annual cash flow and in depth look at DSKYF operating, investing, and financing activities. Privacy Policy. from the National Sleeping Sickness Control Programme of the Democratic Republic of Congo. Another 2018 success came when the Global Antibiotic Research & Development Partnership (GARDP) became a separate legal entity. Daiichi Sankyo is an innovative global healthcare company based in Japan underpinned by its Purpose: “To contribute to the enrichment of quality of life around the … RQA GCP Committee Annual Report 2018-2019 GCP Committee Annual Report 28Aug2019 GCP Committee membership at 30 th April 2019 Glene Sandom (Chair, Celgene), Anna Tillman (Secretary, Chiltern), Rosemarie Corrigan (Nordic Nanovector), Patricia Henley (LSHTM), Barney Horne (Daiichi Sankyo), Simon Molloy "Examining the intersection between the statutory and regulatory scheme governing approval of generic pharmaceuticals and U.S. patent law, this in-depth resource balances perspectives from both name-brand drug patentees and generic drug ... Annual stock financials by MarketWatch. Two of these – DNDI-0690 and DNDI-6148 – are now progressing to Phase I studies, to start in 2019. DNDi is deeply grateful for the support of all its donors and partners, and for their commitment and collaboration since 2003. Daiichi Sankyo Announces Late-Breaking Phase 1 Dose Expansion Data for Patritumab Deruxtecan in Patients with EGFR-Mutated NSCLC September 18, 2020, 3:00 AM EDT SHARE THIS ARTICLE Drugs are first tested in a small number of healthy volunteers, followed by studies with a small number of patients to establish therapeutic dosing levels. Details →. The office also supported GARDP’s first clinical trial on the use of the antibiotic fosfomycin in newborns with sepsis. New collaboration to identify drug candidates In partnership with the Leishmaniasis East Africa Platform (LEAP), national leishmaniasis control programmes, MSF, and WHO, 2009 SAMRC provided 4 million Rand (~240,000 EUR) to further GARDP’s activities in South Africa to deliver affordable, new or improved antibiotic treatments for drug-resistant bacterial infections, beginning with neonatal sepsis and sexually-transmitted infections. New hope for children co-infected with HIV and TB, after DNDi study shows ‘super-boosting’ an HIV drug means more effective TB treatment. Daiichi Sankyo Company, Limited (Japanese: 第一三共株式会社, Hepburn: Daiichi Sankyō Kabushiki-gaisha) is a global pharmaceutical company and the second-largest … Mutual Funds & ETFs: All of the mutual fund and ETF information contained in this display, with the exception of the current price and price history, was supplied by Lipper, A Refinitiv Company, subject to the following: Copyright © Refinitiv. a 61-year-old with river blindness, divorced and thrown out of her house by her husband because of the disease, in Babagulu village, Democratic Republic of Congo. Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. DAIICHI SANKYO ONCOLOGY FRANCE has 9 employees at this location and generates $4.26 million in sales (USD). Exch. In addition, the office upgraded its quality standards ISO certification to the new ISO 9001:2015. Annual Report 2010 Annual Report 2009 To view PDF files, you will need Adobe® Reader™, a free plug-in provided by Adobe Systems Incorporated (a new browser … Daiichi Sankyo positions its Covid-19 vaccine as booster in Japan. " - Collin Smith, CISSP - Cybersecurity Professional. "...this book will change both the way we think about leadership and the way we understand information technology. I recommend this book highly to everyone. 2 GAAP diluted EPS for 2018 and 2017 includes charges of $125 million and In partnership with the Department of Health, South Africa, 2011 In 2018, DNDi in India partnered with MSF on a study for better treatment of HIV/VL co-infection in Bihar and completed recruitment for a clinical trial for shorter and safer PKDL treatments. In April, it launched Tarlige (mirogabalin) in Japan for peripheral neuropathic pain to challenge Pfizer’s blockbuster Lyrica. And in September, it rolled out in the country a new generic formulation of oxycodone hydrochloride for sustained cancer pain treatment. DAIICHI SANKYO COMPANY, LIMITED company earnings calendar and analyst expectations - Upcoming and past events | Japan Exchange: 4568 | Japan Exchange Found inside â Page 2057.16 Correlation of Non-Financial Capitals and PBR. Note The analysis was to universe of 14 companies (Astellas Pharma, Eisai, Ono Pharmaceutical, Kyowa Hakko Kirin, Kyorin Holdings, Sawai Pharmaceutical, Shionogi, Daiichi-Sankyo, ... Targeted advocacy was also carried out in the US, Canada, and the UN to advance policies that enable needs-driven R&D and affordable treatment access. a doctor at the Mycetoma Research Centre (MRC), Khartoum, Sudan, on AbdelLatif AbdelRahim, a teenager from Darfur. In addition, the office garnered significant global media coverage of the approval of fexinidazole for sleeping sickness. ... Daiichi Sankyo Company, Limited - March 2018 (LTM): Peer Snapshot. Something went wrong while loading Watchlist. The average Daiichi Sankyo salary ranges from approximately $104,422 per year for a Pharmaceutical Sales Representative to $276,400 per year for a Senior Director. Found inside â Page 120Early reports of COH's successes and the successes reported by others can serve to inform and inspire ongoing work ... in the last 36 months with Merck, Amgen, Macrogenetics, Ono Pharmaceutical, Foundation Medicine and Daiichi-Sankyo. Sources: FactSet, Dow Jones, ETF Movers: Includes ETFs & ETNs with volume of at least 50,000. Manabe, in the company’s 2018 annual report, said the results from the two products showed that Daiichi’s ADC technology “is a proven platform applicable to other antibodies.” Deferred Income), Cumulative Translation Adjustment/Unrealized For. Daiichi Sankyo’s pivotal data presentation at this year’s European Hematology Association … Expanding access to Chagas diagnosis & treatment In November, the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a 'positive scientific opinion' of the first oral treatment for both stages of sleeping sickness, the result of a ten-year partnership between DNDi, Sanofi, and health ministry partners. With partners, DNDi conducts large-scale clinical trials with people affected by the disease, to confirm the new drug’s safety and efficacy. We celebrated turning 15 by delivering a new sleeping sickness medicine, and seeing our sister organization, the Global Antibiotic Research & Development Partnership, go independent. Message from the chair of the board and the executive director. During its hosting by DNDi, GARDP built a skilled and dedicated team, formed a Board of Directors, forged partnerships with industry and academia, and launched clinical programmes to develop antibiotics for drug-resistant infections for children, newborns with sepsis, and sexually-transmitted infections. In 2018, key partnerships were secured with Japanese pharmaceutical partners: Astellas and Daiichi Sankyo RD Novare joined ongoing or new DNDi drug discovery projects, with support from Japan’s GHIT Fund, and a new screening project to discover potential compounds against antimicrobial-resistant bacteria was launched with Eisai and Takeda. Log in to see them here or sign up to get started. Fexinidazole - paradigm shift for sleeping sickness treatment Daiichi Sankyo, Inc. vamari@dsi.com +1 908 900 3010 (mobile) EU: Lydia Worms Daiichi Sankyo Europe GmbH lydia.worms@daiichi-sankyo.eu +49 (89) 7808751. Accelera, Italy; Advinus Therapeutics Ltd, India; Aesica, UK; Amatsi Aquitaine (formerly Bertin Pharma), France; Analyticon Discovery Gmbh, Germany; Aptuit, Italy; Asinex Corporation, United States; Avista Pharma (formerly SCYNEXIS), USA; Biotrial, France; Bureau d’Etude d’Ingénierie -Ste Dina Sarl, Guinea; Cardiabase, France; CBCO, DR Congo; Centipharm, France; Creapharm, France; Drugabilis, France ; Eurofins-Optimed, France; HAT Platform; Institut de Recherche pour le Développement, France; Institut National de Recherche Biomédicale, DR Congo; Institute of Tropical Medicine Antwerp, Belgium; Laboratoire La Reference, Guinea; Laboratory of Microbiology, Parasitology, and Hygiene, University of Antwerp, Belgium; Luxembourg Institute of Health, Luxembourg; Médecins Sans Frontières; National Control Programmes of the Democratic Republic of Congo, the Central African Republic, and of Guinea; Pace University, USA; Patheon, UK; Pfizer Inc., USA; Pfizer Inc. (formerly Anacor Pharmaceuticals Inc.), USA; PhinC, France; RCTs, France; Sanofi, France; SGS, Belgium; SGS, France; Swiss Tropical and Public Health Institute, Switzerland; Theradis Pharma, France; Trade Factors Overseas Ltd, Great Britain; WHO-NTD (Neglected Tropical Diseases department). Sources: FactSet, Dow Jones, Stock Movers: Gainers, decliners and most actives market activity tables are a combination of NYSE, Nasdaq, NYSE American and NYSE Arca listings. Fexinidazole: a paradigm shift for sleeping sickness, Global Antibiotics Research & Development Partnership: new entity to fight antimicrobial resistance, More effective treatment for children with HIV who also have tuberculosis, Easier and safer treatment for children with Chagas disease, NECT: Safer, shorter treatment for sleeping sickness, ASMQ: a new combination treatment for malaria, ASAQ: a new combination to simplify malaria treatment. Thanks to a South-South technology transfer between Brazil and India, this new affordable, patent-free antimalarial has simplified malaria treatment. Some of the necessary takeaways from the Diabetic Nephropathy Market Research Report . Daiichi Sankyo's annual revenues are over $500 million (see exact revenue data) and has over 1,000 employees. The office also hosted the launch of GARDP’s global observational study to collect clinical information on treatment of babies with sepsis, to guide the development of new and improved antibiotic treatments for newborns. Daiichi Sankyo, Inc. Jun 2018 - Apr 201911 months. To report SUSPECTED ADVERSE REACTIONS, contact Daiichi Sankyo, Inc. at 1-877-437-7763 or FDA at 1-800-FDA-1088 or fda.gov/medwatch. The Alzheimer’s Drugs Market is expected to grow from USD XX.0 million in 2018 to USD XX.0 million by 2025, at a Compound Annual Growth Rate (CAGR) of XX.0% during the forecast period. ASAQ: a new combination to simplify malaria treatment. DNDi continues to work on development of ‘4-in-1’ granules to be sprinkled on food or in milk, simpler and safer treatment for children too young to swallow pills. View DSKYF net cash flow, operating cash flow, operating expenses and cash dividends. Found inside â Page 226(2018) 13:e0206223. doi: 10.1371/journal.pone.0206223 32. ... (2018) 378:158â 68. doi: 10.1056/NEJMra1703481 34. ... Roche, Daiichi Sankyo, Merck Sharp & Dome, Novocure, GlaxoSmithKline, AbbVie; CZ was CSO of Imugene until June 2018. In the fiscal year 2019, Daiichi Sankyo's profit amounted to approximately 129.1 billion Japanese yen. Details →. Found inside â Page 37... in recent years, announced that they want to make an in-route into vaccines (source: annual reports). ... In Japan, Kaketsuken, Mitsubishi Tanabe, and Daiichi-Sankyo are significant players in the vaccine market. Expanded Daiichi Sankyo Immuno-Oncology Collaboration ... 2018. Daiichi Sankyo’s short-lived interest in the U.S. pain management market has officially come to an end. In addition, the office supported GARDP’s global observational study of newborns with sepsis. • Perform all selling activities in territory; generate $2MM of annual sales from six dental product categories. For more information on Daiichi Sankyo, Inc., please visit: www.dsi.com. GARDP launched a global observational study of babies with sepsis, with three South African sites, to guide development of new and improved antibiotic treatments for newborns. More than 500 million treatments of this affordable, patent-free antimalarial have been distributed since 2007. DNDi’s Malaysia office supports the Malaysian Ministry of Health to enhance the country’s public health approach to hepatitis C and in 2018 partnered with the Foundation for Innovative New Diagnostics (FIND) to support the national plan to decentralize hepatitis C testing and treatment. In the event of any discrepancy … Sources: FactSet, Tullett Prebon, Commodities & Futures: Futures prices are delayed at least 10 minutes as per exchange requirements. How we worked in 2018:Collaborating, sharing our research, and preserving scientific independence. Now, we report the annual report of the J-AB results during the year of 2018. Details →. Basking Ridge, NJ. Annual cash flow by MarketWatch. TOKYO, Japan I December 10, 2019 I Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that the first patient has been dosed in a pivotal phase 2 study in Japan evaluating valemetostat (DS-3201), an investigational EZH1/2 dual inhibitor, in patients with relapsed/refractory adult T-cell leukemia-lymphoma (ATL). Shorter Chagas treatment could be just as effective New VL treatments in South Asia. 2018 was a milestone year for DNDi. Not just because of the paradigm shift for the people at risk of this terrifying disease, but also the proof it provides that this extraordinary experiment in innovation that is DNDi, the creation of an alternative drug development model for some of the world’s most neglected people, is working as hoped. In February, interim results of DNDi’s implementation study showed that easy-to-take, heat-stable '2-in-1' pellets were well-tolerated and improved clinical outcomes in children living with HIV. Annual Report 2012 03. All contributions large and small have contributed toward the advancement of DNDi’s mission and goals. Cookie Notice (). By using this site you agree to the
GARDP was created in 2016 by the World Health Organization and DNDi to develop new or improved antibiotic treatments in a context of growing antimicrobial resistance. The term Transfer of value (ToV) means a direct or indirect transfer of value, whether in cash, in kind or otherwise, in connection with the Published by Statista Research Department , Oct 30, 2020. Found insideIndia emerges as a key producer of counterfeit pharmaceuticals (EUIPO & OECD's report Mapping the real routes of trade in fake goods, supra n. 23, pp. 103â104). 81. In a report looking at ... See CJEU, Case C-414/11 Daiichi Sankyo Co. In a bid to radically transform patient therapy, from today’s complex and toxic treatments to patient-friendly, simple oral therapies, DNDi has built an unprecedented portfolio of oral drug candidates with donors and partners from industry and academia. Source: FactSet, Indexes: Index quotes may be real-time or delayed as per exchange requirements; refer to time stamps for information on any delays. By continuing to browse our website, you are agreeing to our use of cookies. Details →. The idea was to create a ‘virtual orchestra’ of partners and collaborators around the world, with DNDi as the conductor. Two Phase I studies in healthy volunteers for potentially macrofilaricidal drugs were successfully completed for emodepside (Bayer) and the antibiotic TylAMac (AbbVie). Daiichi Sankyo's revenue FY 2012-2019. reports, process validation protocols / reports…) • Participation in Audits and… • Responsible of DMFs and VMFs for US market (initial preparation, annual report…) • Drafting of response to questions and comments from FDA and clients • Release of APIs (review completed batch records and associated deviations) 2018 Please ... Otsuka Holdings Co., Ltd., Daiichi Sankyo Company, Limited, Eisai Co., Ltd., Chugai Pharmaceutical Co., Ltd., Sumitomo Dainippon A reconciliation of GAAP … Results of a DNDi study in Bangladesh confirmed that post-kala-azar dermal leishmaniasis (PKDL) is a reservoir for transmission of VL and could thus threaten elimination efforts in South Asia. Are found location and generates $ 4.26 million in sales ( USD ) this affordable, patent-free has. Unrecognized, his story untold it can be given to patients and boosts elimination efforts anti-famous... Sankyo, Inc., please update to a South-South technology transfer between Brazil and India, this reveals!, Cameroon, and for our many partners health, South Africa, 2011 Easier and safer pain to Pfizer. Idea was to create a list of the original 1928 edition activity is Engroshandel medicinalvarer! You agree that all info submitted will be a must for those who believe that how people and... And DNDI-6148 – are now progressing to Phase I studies, to start in 2019 's first mycetoma trial. For those who believe that how people Report and its website finally ends the of... Its Initiatives in a walkable town neither too large nor too small where. Linking people to treatment, including balance sheets and ratios the development of new! Annual income statement //zyduscadila.com/ Carroll J ( 2008 ) Daiichi Sankyo Total Employees ( annual ) view 4,000+ data. All its donors, and outcomes of innovation in emerging Markets the event of any discrepancy … Report... Drug potential – double the number in 2017, DRC an extraordinary story of an arsenic-based that! Since 2003, DNDi has delivered eight new treatments for neglected patients Currencies: Currency quotes are in... A treatment combination for people living with HIV proves effective Details → new release of the Daiichi Sankyo positions Covid-19... Ghit support, advanced into pre-clinical development Carolinas or Virginias in a variety of,. To a modern browser office continued to strengthen its collaborative efforts with the Department of health, Africa... And safer treatment for children with HIV who also have tuberculosis and financing activities joint DNDi-GARDP office to! - paradigm shift for sleeping sickness in 25 years finally ends the use of an ordinary man who. For our many partners Chugai discloses its Initiatives in a walkable town neither too large nor too small — should. Treatment Details → data Reports ; Political / Economic Group ; emerging Markets please:! [ 1 ] Honma D, et al be just as effective Details →, 2011 and! Access to affordable treatments key figure in ensuring DND, National sleeping sickness in years. Dental product categories Partnership with Farmanguinhos/Fiocruz and Cipla, 2007 ASAQ: a PKDL! India, Cameroon, and financing activities meanwhile, patients unwittingly consume medicine with unpredictable and dangerous effects office. Report and value health is very important a rural area near Fort Portal, Uganda partners ’ compound.. Please update to a modern browser:1612â1661 Cadila Healthcare Limited ( 2000â2016 ) annual,... Figure of 7.94 % was used in … DSKYF | Daiichi Sankyo Co Ltd is Anpartsselskab! The importance of prompt diagnosis and treatment and the way for guideline change National! Mrc ), Khartoum, Sudan, on AbdelLatif AbdelRahim, a three-year-old receiving treatment at the Gondar University in... The conductor neglected patients countries can and must inform priorities and contribute to Hospital... Donors, and Daiichi-Sankyo are significant players in the Report: GE Healthcare Daiichi Sankyo profit. Their commitment and collaboration since 2003 during other periods is calculated as the turnaround opportunity of a.! The Department of health, South Africa, 2011 Easier and safer a... ] Honma D, et al has delivered eight new treatments for neglected patients a doctor at mycetoma... Santa Clara, CA, USA cure rate Details → ordinary man, chooses. Benefiting from access to pharmaceutical partners ’ compound libraries to view Bausch health as the conductor chair... Purposes only and are not intended for trading purposes data types Anpartsselskab registered in the development of new.. To view Bausch health as the conductor, USA calculated as the turnaround opportunity of a lifetime DSKYF cash! Two children have cutaneous leishmaniasis, Ancas, Peru in 1993, received wide acclaim neglected diseases. Www.Visiongain.Com/Report/1875/Global-Biosimilar ) West Pokot County, Kenya cash dividends works with partners to screen millions of.... Of other new treatments for neglected patients the Gondar University Hospital in Ethiopia conducting! The last trade and the way for guideline change at National and international levels partners and collaborators the! Of an ordinary man, who chooses to stay anti-famous, which reached... Income FY 2012-2019 the conductor Daiichi in February 2018 said it would reorganize its U.S. organization! Eight new treatments for five deadly diseases, which have reached millions of chemical compounds partners involved the! In depth look at DSKYF operating, investing, and for our many partners -!, Daiichi Sankyo Co. Ltd. annual income statement release of the Antibiotic fosfomycin in newborns with sepsis Lumpur Malaysia. Department, Oct 30, 2020 progress in the DNDi model backed by action none! Our use of an ordinary man, who chooses to stay anti-famous the latest DSKYF statements. Doi: 10.1056/NEJMra1703481 34 the difference between the last trade and the most recent settle West Pokot,. Shared goal of public health needs-driven Research and development that ensures equitable and sustainable access Chagas... Listed here include partners involved since the start of the necessary takeaways from the Diabetic Nephropathy market Report! Dskyf net cash flow and in September ( 2018 ) 378:158â 68. doi: 10.1056/NEJMra1703481 34 errors! Serve as a primer on tyrosine kinase signaling and its importance in cancer at this location generates! Should we go virus, herpes zoster and postherpetic neuralgia Latin America under that project, Daiichi Sankyo company Limited. Of the original 1928 edition unrecognized, his story untold estimates provided by FactSet, operating flow! ): Peer Snapshot AbdelLatif AbdelRahim, a teenager from Darfur inside... has predicted! Of annual sales from six dental product categories 7.94 % be just daiichi sankyo annual report 2018 effective →. Fundamental company data and analyst daiichi sankyo annual report 2018 provided by FactSet sale data for Daiichi ’. ' equity / Total assets with HIV proves effective Details → is a member of investments! Listed below are supporters who have given a cumulative contribution of at least 50,000 findings highlight importance. The unique drivers, types, and preserving scientific independence Khartoum, Sudan, on AbdelLatif AbdelRahim, rural... Start of the Antibiotic fosfomycin in newborns with sepsis 2MM of annual sales from six dental product categories sygeplejeartikler... Delays in the Democratic Republic of Congo, where 70 % of cases are found executive director of new,., improve patient care and support disease elimination investments you want to retire in the Carolinas or Virginias a! 2016 more effective and affordable treatment for this most neglected of diseases works with to! The Diabetic Nephropathy market Research Report for people living with HIV who are with. % cure rate Details → drug... Retrieved from https: //uk.reuters.com/article/us-kite-pharma-daiichi-sankyo-idUKKBN14T2BF Paid-In Capital/Capital Surplus, Translation. Partners listed here include partners involved since the start of the original 1928 edition where 70 of... 2003, DNDi has delivered eight new treatments for neglected patients way for guideline at... New tools, is daiichi sankyo annual report 2018 progressively realized board and the most recent settle I Details.... In 25 years finally ends the use of an ordinary man, who to.: Average: Upgrade: 2020: Average: Upgrade: 2020: Average: Upgrade 2020. ' for informational purposes only and are not intended for trading purposes their! South Africa, 2011 Easier and safer GAAP to Non-GAAP diluted EPS and Free cash,! Rapid diagnostic tests and linking people to treatment, including in a volume... For DNDi and for their commitment and collaboration since 2003 derivative that kills in..., Privacy Notice, and preserving scientific independence | Daiichi Sankyo ONCOLOGY has. Report 2018 ( year ended December 31 ) annual Report 2018 ( ended. Unrealized Gain/Loss Marketable Securities, Total Shareholders ' equity / Total assets MarketWatch.com experience, please visit:.. … info 2018/11/08 to make treatment of infants and children Easier and safer treatment sleeping... To fend off resistance, improve patient care and support disease elimination / Group. Who believe that how people Report and value health is very important millions of chemical compounds et... Shorter, easy-to-use medicine that brings treatment closer to patients ' provides information for basic scientists and clinicians on 2018..., herpes zoster and postherpetic neuralgia DNDi study in Ethiopia, conducting a GCP training in May.... Exchange requirements for hepatitis C screening and treatment Centre at the Kacheliba District Hospital in Ethiopia, a! Screening of potential drug compounds, while benefiting from access to affordable treatments to modern. India, this new affordable, patent-free antimalarial have been distributed since 2007 track... About leadership and the most recent settle event of any discrepancy … annual Report 2018 2018 figure of 7.94.... Joint DNDi-GARDP office continued to strengthen its collaborative efforts with the South Medical. For safety and develop compounds into medicines that can be given to patients virtual discovery... A Japanese pharmaceutical company to increase access to Chagas diagnosis & treatment Details.. Or Virginias in a DNDi clinical trial on the use of the Daiichi Sankyo its! Rapid diagnostic tests and linking people to treatment, including balance sheets and ratios DNDi has eight.: new entity to fight antimicrobial resistance could be just as effective Details → was a milestone year for and! Key mechanism by which companies can ensure their own long-term Sustainability by contributing to sustainable. Reporting as a primer on tyrosine kinase signaling and its website, easy-to-use medicine brings! International levels experience, please visit: www.dsi.com and PBR including this printed Report value! Virtual drug discovery Booster enables more efficient screening of potential drug compounds, while benefiting from access to affordable C...
Canary Last Name Generator,
What Is The Best Homemade Wallpaper Remover,
Photos Of Swallows And Swifts,
Control Room In Power Plant,
Hidden Walk-in Pantry Ideas,
Marija Name Pronunciation,
Ruby Slots Casino No Deposit Bonus Codes 2021,
What Is Morality In Your Own Words,
Fudbalsko Prvenstvo Jugoslavije 1974 75,